about
An improved reverse genetics system for influenza A virus generation and its implications for vaccine productionGeneration of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse geneticsAssessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the NetherlandsInjectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics - a systematic literature reviewInfluenza virus hemagglutinin stalk-based antibodies and vaccinesReview of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine AnfluĀ®Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 virusesEfficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza virusesHigh-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase ActivityCAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferretsH5 influenza, a global update.Universal influenza virus vaccines and therapeutic antibodies.Prediction of Peaks of Seasonal Influenza in Military Health-Care DataAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetPandemic influenza: antiviral preparedness and health care workers.Vaccines for a potential influenza pandemic.Economics of neuraminidase inhibitor stock piling for pandemic influenza, SingaporeImmunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccineQuantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemicDirect ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutininPotency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice.Influenza virus PB1 and neuraminidase gene segments can cosegregate during vaccine reassortment driven by interactions in the PB1 coding region.A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccineSurvey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics.Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Current and emerging cell culture manufacturing technologies for influenza vaccines.Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.Avian and pandemic influenza: progress and problems with global health governance.Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in HumansEfficient generation of influenza virus with a mouse RNA polymerase I-driven all-in-one plasmidA plant-produced influenza subunit vaccine protects ferrets against virus challengeSuperior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.Continuous cell lines as a production system for influenza vaccines.Novel universal influenza virus vaccine approachesConstruction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.Formulation of microneedles coated with influenza virus-like particle vaccine.
P2860
Q24537680-6951AEC5-192C-4B64-B703-A3A546BF6CB6Q24607062-4F7EB1E7-C702-46AE-9D07-D55886E7ADBAQ24645393-092FE2F4-9A3F-4AFC-973D-BA96AD3385D4Q24645944-9803F63E-AD2F-4A1A-A626-65E551AC0489Q26769664-1F0492F3-9A5F-4D1F-9EA2-221C9AAB2371Q27001190-2B5311CB-54E3-4B30-82CC-1149DC15DD8AQ27022914-773112BC-50EF-49B5-B197-04D5D741E948Q28365124-06998ADB-7143-4531-8D07-EAA744C28B89Q28473051-0A50D7AF-C4E6-42EF-97FE-2ED60291592DQ28552500-EAE1A686-3F43-4788-9A88-3F08DD71E6B3Q28741710-3A6139EE-2DA4-42E8-A625-20E17C504DE0Q30151309-F55E7D54-9A9B-476F-A807-ECD2F11FAA1BQ30151337-63083A2D-C904-4AC8-8353-42C542D07BF2Q30152065-6FFEF293-37A2-4530-9AE4-D27524939D0FQ30227194-B448A9FD-0C0F-402D-9614-EBA2B4FD8DDAQ30227214-E8747C5E-A5CD-4945-8C70-5FBDFB4415C1Q30229470-C3A766BB-E0A0-4ADA-9A78-800364535A27Q30353079-C5482BEE-3655-4AAB-B7E5-DA6AB820536EQ30353632-A98D3295-2E17-46D5-B44D-E1E6C75570D9Q30360870-26AC9EE6-0F34-49A4-BAA8-FE6E552C45EDQ30361736-0F0C87EE-63D7-4121-BF7B-CA64FBA6C29CQ30362515-652CBC3E-9C50-4798-BE57-B0A4C9E5F99DQ30362983-A678AC37-653A-4E6A-A3B8-8D28093E8455Q30365391-AF169E96-4B66-4332-A49D-890AE1240B7CQ30365396-6D62987E-EE23-4A8D-91CA-7BC1D966E8F9Q30368555-0630510B-D7F8-4E7A-90A1-40CD7AD2C019Q30369679-7DFA3FE2-ED52-44F1-B014-BCCD17ED0C60Q30372274-E37B98E9-4CBF-4DC3-99A1-6C6CCDA3EDF1Q30373128-7DE9978A-8664-4B7A-9412-1058F9DB35B7Q30374733-9FB6E165-67F0-4CDD-8A2A-05D944882AEEQ30375514-86A6FA55-A5EF-48E0-982E-D31CC47DF031Q30375536-5A7B305D-353F-4C42-B12E-DB752A0B0C9FQ30375769-27074F90-2FBD-4DF2-A71E-F0D886BA4E53Q30375917-7AF70028-BE9B-44B7-B207-E675F2CCAA9AQ30377250-C1525253-524F-4F30-AB9F-28643F3267FEQ30379493-871F32B2-64ED-4DE3-9415-D44D98761237Q30382947-99E78F91-F43D-4855-92FB-55BBD7E60793Q30385071-66A3B8A4-79BB-4D12-87A6-A5D351239A55Q30387186-0936C466-7260-4123-A051-C74EBA1E8BBAQ30392132-5ADB8A7B-0E24-4E6E-9B59-AC8401651922
P2860
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003幓ć®č«ę
@ja
2003幓å¦ęÆęē«
@wuu
2003幓å¦ęÆęē«
@zh
2003幓å¦ęÆęē«
@zh-cn
2003幓å¦ęÆęē«
@zh-hans
2003幓å¦ęÆęē«
@zh-my
2003幓å¦ęÆęē«
@zh-sg
2003幓åøč”ęē«
@yue
2003幓åøč”ęē«
@zh-hant
name
The annual production cycle for influenza vaccine.
@en
The annual production cycle for influenza vaccine.
@nl
type
label
The annual production cycle for influenza vaccine.
@en
The annual production cycle for influenza vaccine.
@nl
prefLabel
The annual production cycle for influenza vaccine.
@en
The annual production cycle for influenza vaccine.
@nl
P1433
P1476
The annual production cycle for influenza vaccine.
@en
P2093
Catherine Gerdil
P304
P356
10.1016/S0264-410X(03)00071-9
P407
P577
2003-05-01T00:00:00Z